Sudarshan Pharma to acquire 30% stake in Sudarshan Maven Pharma

Sudarshan Pharma Industries Ltd announced that its Board of Directors has approved the acquisition of 3,000 equity shares, representing 30.00% of the paid-up capital, in Sudarshan Maven Pharma Private Limited. The acquisition, valued at a cash consideration based on valuation, is expected to be completed by December 31, 2026. Upon completion, Sudarshan Maven, which is primarily engaged in pharmaceutical and healthcare products and has not yet commenced commercial activities, will become a wholly-owned subsidiary of Sudarshan Pharma. This move aligns with Sudarshan Pharma's existing business activities.